Table 2 Trend of treatment policy for childhood acute myeloid leukemia by study period.

Abbreviations: AML 2012, double induction regimen consisting of idarubicin (IDA) or mitoxantrone plus cytarabine based chemotherapy; BM, bone marrow; KSBRM, idarubicin plus N4-behenoyl-1-β-D-arabinofuranosyl cytosine (BHAC) based chemotherapy; PB, peripheral blood; UCB, umbilical cord blood.

Blood Res 2018;53:25~34 https://doi.org/10.5045/br.2018.53.1.25